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The opioid system plays a crucial role in several physiological processes in the CNS and in the periphery. It has also been
shown that selective opioid receptor agonists exert potent inhibitory action on pruritus and pain. In this study we examined
whether two analogues of Salvinorin A, PR-37 and PR-38, exhibit antipruritic properties in mice.
EXPERIMENTAL APPROACH
To examine the antiscratch effect of PR-37 and PR-38 we used a mouse model of compound 48/80-induced pruritus. In order
to elucidate the mechanism of action of tested compounds, specific antagonists of opioid and cannabinoid receptors were
used. The effect of PR-37 on the CNS was assessed by measuring motor parameters and exploratory behaviours in mice.
KEY RESULTS
PR-37 and PR-38, jnjected s.c., significantly reduced the number of compound 48/80-induced scratching behaviours in mice
in a dose- and time-dependent manner. PR-38 was also active when orally administered. The antiscratch activity of PR-37 was
blocked by the selective κ opioid receptor antagonist, nor-binaltorphimine, and that of PR-38 by the selective μ opioid
receptor antagonist, β-funaltrexamine.
CONCLUSION AND IMPLICATIONS
In conclusion, a novel framework for the development of new antipruritic drugs derived from salvinorin A has been validated.
Abbreviations
β-FNA, β-funaltrexamine; CB1, cannabinoid receptor type 1; DAMGO, [D-Ala2-N-MePhe4-Gly-ol]-enkephalin; DOR,
δ-opioid receptor; HA, high analgesia; KOR, κ-opioid receptor; LA, low analgesia; MOR, μ-opioid receptor; NLTR,
naltrindole; NLX, naloxone; norBNI, nor-binaltorphimine; SA, salvinorin A; TRP, transient receptor potential channel
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Introduction
Pruritus is defined as a short- or long-term localized or gen-
eralized itch. There is no precise definition of itch, but it is
generally referred to as an unpleasant cutaneous sensation,
leading to a desire to scratch. Itch may be manifested by
different sensations, such as tingling, crawling or irritation,
but the common feature of itch-related sensations is their
peripheral origin, in particular the skin (Bigliardi and
Bigliardi-Qi, 2014). Pruritus negatively affects quality of life;
it may lead to scratch-related skin damage, sleep disturbance
and could even cause reactive depression (Benecke et al.,
2013). Chronic pruritus may occur at any age; however, its
prevalence is higher in older patients than in children and
young adults (Benecke et al., 2013). Chronic pruritus may be
caused by some diseases, such as atopic dermatitis, liver dis-
eases or bile secretion disorders.
Clinical and molecular studies in patients affected by pru-
ritus lead to identification of specific mediators and receptors
involved in the development of itch, such as histamine 4
receptor, interleukin-31, together with opioid receptors,
gastrin-releasing peptide receptor, neurokinin-1 receptor and
transient receptor potential channel ion channels (Benecke
et al., 2013; Bigliardi and Bigliardi-Qi, 2014). Regardless of the
factor that triggers the sensation of itch, the first step in its
induction is the interaction between the skin cells, for
instance, keratinocytes, melanocytes, Merkel cells, masto-
cytes, endothelial cells and fibroblasts, and peripheral non-
myelinated sensory C-fibres (Bigliardi and Bigliardi-Qi, 2014).
Neural signals are further transduced through the peripheral
nerves, dorsal root ganglia and spinal cord to the higher
centres in the brain (Bigliardi and Bigliardi-Qi, 2014). These
signals can be modulated at each level of transduction to
decrease the sensation of itch, as well as pain.
Three main types of opioid receptors, namely, μ-opioid
receptor (MOR), κ-opioid receptor (KOR) and δ-opioid recep-
tor (DOR), mediate the actions of opioid drugs and endog-
enous opioid peptides. They are located both in the CNS and
the periphery, including neurons (located in the dermis, epi-
dermis and around hair follicles) and immune cells (mac-
rophages, neutrophils) (Bigliardi et al., 2009; Bigliardi and
Bigliardi-Qi, 2014; Salaga et al., 2013; Sobczak et al., 2014).
Opioid receptors mediate several biological functions and are
attractive molecular targets in the development of new thera-
peutic agents. In the CNS, opioid agonists regulate, among
others, pain perception and antinociception, mood, cogni-
tive function and locomotor activity (Fichna et al., 2009a;
Sobczak et al., 2014). On the cellular level, activation of
opioid receptors results in inhibition of adenyl cyclase,
increase in K+ conductance and activation of mitogen-
activated protein kinases (Wang et al., 2005).
Recently, a broader attention has been given to KORs and
their ligands, which may become a target in the treatment of
pruritus. It is generally accepted that KOR signalling sup-
presses, while MOR signalling stimulates itch responses.
However, a specific mechanism underlying this difference is
not well understood. For example, pharmacological blockade
of KOR by its selective antagonist nor-binaltorphimine
(norBNI) was shown to induce scratching behaviour (Kamei
and Nagase, 2001) Other studies found that centrally admin-
istered selective MOR agonists, such as [D-Ala2-N-MePhe4-
Gly-ol]-enkephalin (DAMGO), produce facial scratching in
mice (Kuraishi et al., 2000). Moreover, spinal analgesics
acting on MOR, such as morphine, produce a dose-dependent
itch in primates (Ko and Naughton, 2000). This side effect
may lessen its potential in pain relief.
In this study, we characterized the antiscratch effect of the
selective KOR agonist salvinorin A (SA), a natural diterpenoid
isolated from the Mexican plant Salvia divinorum, and its two
Michael acceptor-type analogues, methyl salvinorin B-2-O-
malonate (PR-37) and 2-O-cinnamoylsalvinorin B (PR-38)
(Fichna et al., 2009b; Polepally et al., 2013; Polepally et al.,
2014). In the in vitro studies, these two analogs displayed high
affinity at KOR with Ki values of 2.0 ± 0.9 and 9.6 ± 2.0 nM for
PR-37 and PR-38, respectively (Polepally et al., 2013; 2014),
and potently inhibited adenylate cyclase in live HEK293 cells
with EC50 values of 137 ± 15 and 7 ± 1 nM respectively
(Polepally et al., 2013; 2014). Of note, recently we showed
that PR-38 has neither hallucinogenic nor anxiolytic or anxi-
ogenic effects in mice (Salaga et al., 2014b). Here we per-
formed similar behavioural tests to exclude the potential
CNS-related effects of PR-37.
The results of this study showed that PR-37 and PR-38
potently attenuated pruritus in mice and confirmed the
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Methods
Animals
All animal care and experimental protocols were in accord-
ance with the European Communities Council Directive
2010/63/EU and Polish legislation acts concerning animal
experimentation. The experimental protocol was approved
by the Local Ethics Committee at the Medical University of
Lodz (#700/2012). Efforts were made to minimize animal
suffering and to reduce the number of animals used. All in
vivo experiments have been performed in accordance with
ARRIVE guidelines (for details, see McGrath et al., 2010). All
studies involving animals are reported in accordance with the
ARRIVE guidelines for reporting experiments involving
animals (Kilkenny et al., 2010; McGrath et al., 2010). A total
of 490 animals were used in the experiments described here.
Swiss-Webster mice selectively bred towards high anal-
gesia (HA) and low analgesia (LA) (Panocka et al., 1986)
were obtained from the Institute of Genetics and Animal
Breeding at the Polish Academy of Sciences. The selection
process is briefly described below. Outbred mice were forced
to swim for 3 min in water (20°C). Two minutes after com-
pletion of the swim, the latency of the nociceptive reflex on
a hot plate (at 56°C) was measured. Males and females with
the longest (50–60 s) and the shortest (<10 s) post-swim
latencies of the hind paw flick or lick response were chosen
as progenitors of the HA and the LA lines respectively. A
similar procedure was repeated in each offspring generation,
and only subjects displaying the longest and the shortest
post-swim hotplate latencies were mated to maintain the
HA and the LA lines respectively. HA mice were used to
compare behavioural itch response between these two lines.
In all other experiments described in this study, we used LA
mice. Preliminary experiments revealed that the response of
LA mice to a pruritus-inducing agent was similar to that of
normal Swiss-Webster mice. In all experiments, we used
male mice weighing 22–30 g (6–8 weeks of age). The
animals were housed at a constant temperature (22°C) and
maintained under a 12 h light/dark cycle (lights on
6:00 a.m.) in sawdust-lined plastic cages with access to
chow pellets and tap water ad libitum.
Induction of pruritus and measurement of
antiscratch activity
To measure the antiscratch effect, we used a model described
by Kuraishi et al. (1995) with some modification. Briefly,
each mouse was weighed and allowed to acclimatise for at
least 1 h in an individual observation cage. Vehicle, SA, ICI
204 448, PR-37 and PR-38 were injected subcutaneously (s.c.,
100 μL) into the flank before the s.c. injection of the pruri-
togen compound 48/80 (0.5 mg·mL−1, 100 μL) into the back
of the neck (interscapular region). Opioid and cannabinoid
antagonists were injected s.c. (100 μL) before agonists, into
the opposite flank of the body. Oral administration of PR-37
and PR-38 was performed in the volume of 150 μL. After
injection of the pruritogen compound, mice were returned
to observation cages and the number of hind leg scratching
movements directed to the neck was counted for 30 min.
Mice were used only once; all experiments took place
between 7 and 11 a.m.
Pharmacological treatments
SA was injected s.c. at 10 mg·kg−1, 45 min before compound
48/80. A reference antipruritic, ICI 204 448, was administered
s.c. at a dose of 10 mg·kg−1, 45 min before 48/80 compound.
In the dose–effect experiments, PR-37 and PR-38 were
injected at doses of 1, 3, 5, 10 and 20 mg·kg−1 (s.c.) 45 min
before the 48/80 compound. In the time-course experiments,
PR-37 and PR-38 were administered at 10 mg·kg−1 (s.c.) 15, 45,
90 and 120 min before administration of 48/80 compound.
DOR and cannabinoid receptor type 1 (CB1) antagonists were
administered s.c. 30 min before PR-37 and PR-38 MOR
and KOR antagonists as well as naloxone (NLX) were admin-
istered either 30 or 120 min before PR-37 and PR-38
(to ensure their selectivity). The antagonists were used at
the following doses: naltrindole (NLTR, 10 mg·kg−1),
N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-
4-methyl-1H-pyrazole-3-carboxamide (AM 251, 1 mg·kg−1),
β-funaltrexamine (β-FNA, 1 mg·kg−1), norBNI (10 mg·kg−1)
and NLX (1 mg·kg−1). Doses were selected based on the pre-
liminary studies and published data (Chen et al., 2014; Salaga
et al., 2014a,b; Taylor et al., 2014). In experiments with oral
administration, PR-37 and PR-38 were gavaged orally (p.o.) at
a dose of 10 mg·kg−1, 45 min before the 48/80 compound.
Control animals received vehicle (s.c. or p.o.) alone. In the
measurements of spontaneous locomotor activity, morphine
and SA were administered s,c, at 5 and 10 mg·kg−1, respec-
tively, 30 min prior to the test. None of the antagonists influ-
enced the observed parameters when given alone.
Measurement of locomotor activity
Locomotor activity was assessed as described previously by
Salaga et al. (2014b). Briefly, measurement was made auto-
matically in a Digiscan actimeter (Omnitech Electronics Inc.,
Columbus, OH, USA). The device measured horizontal dis-
placements and vertical movements. Animals were placed
individually in 20 × 20 × 30 cm compartments. The responses
were expressed as the number of crossed infrared beams by
mouse during six consecutive 10 min periods.
Elevated O-maze test
To identify differences in exploratory and anxiety-related
behaviour, the elevated O-maze test was used, as described
earlier by Salaga et al. (2014b). The maze consisted of a grey
plastic runway (width 6 cm, outer diameter 46 cm, 50 cm
above ground level), covered with black cardboard paper to
prevent mice from slipping off. The maze consisted of two
opposing open and two opposing sectors protected by inner
and outer walls (height 10 cm). The maze was illuminated
with 25 Lux. At the beginning of the experiment, animals
were placed in one of the protected sectors and observed for
5 min. The following parameters were analysed: total time
spent in the open and closed compartments, and total dis-
tance travelled in open and closed compartments.
Catwalk quantitative gait analysis test
The quantitative analysis of the gait was performed as
described recently by Vandeputte et al. (2010) and Salaga
et al. (2014b). The Catwalk™ is a video-based analysis system
to measure gait parameters in voluntarily walking mice
(Noldus, Wageningen, The Netherlands). The system meas-
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ures various parameters of footfalls in a dynamic manner.
When the animal crosses the walkway, the areas of contact
between paws and the base are being illuminated. In this way
the different paw contacts are visualized and multiple param-
eters are calculated. Here, in order to examine whether PR-37
affects the CNS-derived motor function, several selected
parameters were analysed, including run duration, intensity
of the paws (signal depends on the strength of contact
between the paw and the glass plate), print width (width of
the complete paw print), print length (length of the complete
paw print), print area (surface area of the complete paw
print), maximal area of print, swing (duration of the lack of
contact with the runway in a step cycle), swing speed (speed
of the paw during swing), stand time, stride length, step cycle
and body speed. For data collection, three runs per animal
were performed by placing the animal in front of the start
zone of the catwalk runway. Analysis was performed on a
minimum of four normal step sequence patterns in each
uninterrupted run.
Data analysis
Statistical analyses were performed using PRISM 5.0 (Graph-
Pad Software Inc., La Jolla, CA, USA). The data are expressed
as means ± SEM. Student’s t-test was used to compare single
treatment means with control means. ANOVA followed by
Newman–Keuls post hoc test was used for analysis of multiple
treatment means. P values ≤ 0.05 were considered statistically
significant.
Materials
All drugs and reagents, unless otherwise stated, were pur-
chased from Sigma-Aldrich (Poznan, Poland). SA (purity: 99%
by high-performance liquid chromatography) was isolated
from S. divinorum leaves, purchased from The Sage Wisdom
Salvia Shop (Malibu, CA, USA) by one of the authors
(J.K.Z.). PR-37 and PR-38 were synthesized from SA at the
Department of Pharmacognosy, University of Mississippi,
USA, as described earlier (Polepally et al., 2013; 2014). Nor-
binaltorphimine dihydrochloride, β-FNA hydrochloride,
NLTR hydrochloride and AM 251 were purchased from Tocris
Bioscience (Ellisville, MO, USA). Drugs were dissolved in 5%
DMSO in saline, which was used as vehicle in control experi-
ments. The vehicles in the used concentrations had no effects
on the observed parameters.
Results
Mice with hyperactivity of the endogenous
opioid system are resistant to compound
48/80-induced pruritus
First, we compared the effect of 48/80 compound on behav-
ioural itch response in LA and HA mice. LA mice displayed a
significant susceptibility to compound 48/80-induced pruri-
tus manifested by the high number of scratches per 30 min of
observation (Figure 1). On the contrary, HA mice were highly
resistant to compound 48/80-induced pruritus. LA mice
treated with SA at the dose of 10 mg·kg−1 s.c. showed a lower
number of scratches than vehicle-treated animals, but the
difference did not reach statistical significance.
PR-37 and PR-38 protect against compound
48/80-induced pruritus in a dose- and
time-dependent manner
To test the antiscratch effect of PR-37 and PR-38, we used a
model of compound 48/80-induced pruritus. As shown in
Figure 2A and B, both PR-37 and PR-38 reduced the number
of compound 48/80-induced scratching behaviours in a dose-
dependent manner. The effect of both compounds was statis-
tically significant after administration at the dose of 10 and
20 mg·kg−1. Additionally, we used a well-known antipruritic, a
peripherally restricted KOR agonist, ICI 204 448, as a refer-
ence compound. ICI 204 448 (10 mg·kg−1, s.c.) significantly
reduced the number of compound 48/80-induced scratches
and its effect was stronger than that of PR-37 and PR-38
(Figure 2C).
Encouraged by the above mentioned data, we examined
the time-course of the antiscratch effect of PR-37 and PR-38.
As shown in Figure 3A and B, the compounds (10 mg·kg−1,
s.c.) exhibited a different duration of action in vivo. The
antiscratch effect of PR-37 emerged 45 min after injection
and was present until 90 min post-administration. The effect
rapidly vanished between 90 and 120 min after administra-
tion. In the case of PR-38, a significant antiscratch activity
was only present 45 min after administration, then it gradu-
ally faded between 45 and 120 min post-administration.
PR-37 and PR-38 exhibit different
mechanisms of action in vivo
To examine the mechanism of the antiscratch activity of
PR-37 and PR-38, we used specific opioid and cannabinoid
receptor antagonists. Although in the in vitro tests both com-
pounds displayed affinity only for opioid receptors, in previ-
ous studies we observed that certain biological effects of
PR-38 are blocked by the CB1 receptor antagonist AM 251,
which is why it was used in this study (Salaga et al., 2014b,c).
The effect of both compounds was inhibited by the non-
selective opioid receptor antagonist NLX; however, the dif-
ference did not reach statistical significance (Figures 4B and
5B). As shown, PR-37 (Figure 4) and PR-38 (Figure 5) exhib-
ited different mechanisms of action in vivo. The antiscratch
effect of PR-37 (10 mg·kg−1, s.c.) was blocked by the KOR
Figure 1
Pruritic effect of 48/80 compound in LA versus HA mice. Figure
shows data for vehicle-treated LA and HA mice, and SA-treated LA
mice (10 mg·kg−1, s.c.). Data represent mean ± SEM of n = 6–10
animals. ***P < 0.001, as compared with the LA group.
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antagonist norBNI (10 mg·kg−1, s.c.), whereas the effect of
PR-38 (10 mg·kg−1, s.c.) was inhibited by the MOR antagonist
β-FNA (10 mg·kg−1, s.c.). Neither NLTR nor AM 251 blocked
the antiscratch activity of PR-37 and PR-38. Experiments with
β-FNA and norBNI have been performed with two different
time gaps between the antagonist and the test compound
treatments to ensure their selectivity at MOR and KOR respec-
tively. As shown in Figures 4B and 5B, extending the interval
between treatments to 120 min did not change the outcomes
of the experiment.
To further confirm the selectivity of β-FNA and norBNI at
MOR and KOR, we examined whether they influence the
effects elicited by morphine and SA on mouse locomotor
activity. The hyperactivity induced by morphine was blocked
by pretreatment with β-FNA (1 mg·kg−1, s.c.), but not norBNI
Figure 2
The effect of PR-37, PR-38 and ICI 204 448 on compound 48/80-
induced pruritus in mice. (A) Effect of s.c. administration of PR-37
(1–20 mg·kg−1) on the number of scratches per 30 min. (B) Effect of
s.c. administration of PR-38 (1–20 mg·kg−1) on the number of
scratches per 30 min. (C) Effect of s.c. administration of a reference
drug ICI 204 448 (10 mg·kg−1) on the number of scratches per
30 min. Data represent mean ± SEM of n = 6–10 animals. *P < 0.05,
**P < 0.01, ***P < 0.001, as compared with the control group.
Figure 3
The time-course of the antiscratch activity of PR-37 and PR-38 after
a single s.c. administration at the dose of 10 mg·kg−1 in mice.
(A) Time-course of the effect of PR-37 on the number of scratches
per 30 min. The strongest effect occurs 90 min post-administration
(B) Time-course of the effect of PR-38 on the number of scratches
per 30 min. The strongest effect occurs 45 min post-administration.
Data represent mean ± SEM of n = 8–10 mice for each experimental
group. *P < 0.05, ***P < 0.001, as compared with the control group.
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(10 mg·kg−1, s.c.; Supporting Information Fig. S1A). The
hypoactivity induced by treatment with SA was blocked by
norBNI (10 mg·kg−1, s.c.), but not β-FNA (1 mg·kg−1, s.c.; Sup-
porting Information Fig. S1B).
PR-38 exhibits antiscratch activity after
p.o. administration
We also examined the antiscratch activity of PR-37 and PR-38
after p.o. administration. As shown in Figure 6A, PR-37
reduced the number of scratches, but the difference did
not reach statistical significance but PR-38 significantly
reduced the number of scratches after p.o. administration
(Figure 6B).
PR-37 does not affect exploratory behaviour
or anxiety levels in mice, but it impairs
motor functions
SA, which is a parent compound of PR-37 and PR-38, is
known for its CNS-related actions, such as hallucinogenic
episodes. Previously, we have shown that PR-38 does not
influence CNS-related behaviours after systemic administra-
tion (Salaga et al., 2014b). Here we investigated the effect of
PR-37 in the CNS using appropriate mouse models. The influ-
ence of the i.p. administration of PR-37 on mouse locomotor
activity was measured over six consecutive periods of 10 min
each. The drug administered at a dose of 10 mg·kg−1 did not
modify horizontal or vertical locomotor activity in any of the
time periods of the test (Figure 7A and B).
Figure 4
Antiscratch effect of s.c. administration (10 mg·kg−1) of PR-37 alone
or in the presence of opioid and cannabinoid receptor antagonists.
(A) Antiscratch effect of PR-37 is blocked by KOR antagonist norBNI
(10 mg·kg−1, s.c.) administered 30 min prior to the test compound
but not MOR, DOR and CB1 receptor antagonists (β-FNA, NLTR and
AM 251 respectively). (B) Antiscratch effect of PR-37 is blocked by
the non-selective opioid antagonist NLX (1 mg·kg−1, s.c.) and KOR
antagonist norBNI (10 mg·kg−1, s.c.) administered 120 min prior to
the test compound. Data represent mean ± SEM of n = 6–10 mice for
each experimental group. *P < 0.05, **P < 0.01, as compared with
the control group. #P < 0.05, as compared with PR-37.
Figure 5
Antiscratch effect of s.c. administration (10 mg·kg−1) of PR-38 alone
or in the presence of opioid and cannabinoid receptor antagonists.
(A) Antiscratch effect of PR-38 is blocked by MOR antagonist β-FNA
(1 mg·kg−1, s.c.) administered 30 min prior to the test compound,
but not KOR, DOR and CB1 receptor antagonists (norBNI, NLTR and
AM 251 respectively). (B) Antiscratch effect of PR-38 is blocked by
the non-selective opioid receptor antagonist NLX (1 mg·kg−1, s.c.)
and MOR antagonist β-FNA (1 mg·kg−1, s.c.) administered 120 min
prior to the test compound. Data represent mean ± SEM of n = 6–10
mice for each experimental group. *P < 0.05, **P < 0.01, as com-
pared with the control group. #P < 0.05, as compared with PR-37 or
PR-38.
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To test the effect on exploratory behaviour and potential
anxiogenic or anxiolytic activity of PR-37, an elevated
O-maze test was used. No significant differences were found
for measures of anxiety, such as the percentage of time spent
in open and closed sectors after i.p. administration of PR-37
at a dose of 10 mg·kg−1 (Figure 7C).
We also analysed the gait parameters of mice after i.p.
administration of PR-37 at a dose of 10 mg·kg−1. Eleven
parameters of gait were measured for front and hind paws
separately; four of them changed significantly after adminis-
tration of PR-37 in comparison with control animals, includ-
ing intensity of the paw prints (Figure 7D), print width
(Figure 7E), print area (Figure 7F) and maximal area of print
(Figure 7G). Other parameters, such as swing (Figure 7H),
swing speed (Figure 7I), run duration, stand time, print
length, stride length, step cycle and body speed (data not
shown), were not changed after administration of PR-37.
Discussion
In this study, we showed that two derivatives of SA, PR-37 and
PR-38, attenuate pruritus in mice by activation of opioid
receptors. Of note, these two compounds exhibited different
pharmacological features, such as bioavailability, as well as
duration and mechanism of action. Furthermore, we have
confirmed the endogenous opioid system as an attractive
pharmacological target for antipruritic drugs.
To date, several studies suggested that itch sensation is
closely associated with opioid receptor-dependent signalling.
For example, Bergasa et al. (1993) found that plasma obtained
from patients with pruritus administered into the medullary
dorsal horn, which is the site of action of opiates in produc-
ing facial scratching, elicited facial scratching activity in
monkeys, and this effect was abolished by the administration
of the opioid receptor antagonist NLX (see Bigliardi et al.,
2009; Benecke et al., 2013; Bigliardi and Bigliardi-Qi, 2014).
In our study we add another line of evidence supporting the
involvement of opioid receptors in the modulation of itch
sensation by showing that mice bred selectively towards an
increased activity of the endogenous opioid system (HA) are
resistant to pruritus compared to mice exhibiting normal
opioid system activity (LA).
There is a strong body of evidence based on animal and
human studies supporting the hypothesis that the activation
of KOR protects against pruritus (see Benecke et al., 2013;
Bigliardi and Bigliardi-Qi, 2014; Ko, 2014). Moreover, some
observations indicate the existence of a link between KOR
and its endogenous agonists, dynorphins, and pruritic skin
diseases. Immunohistochemical studies revealed down-
regulation of KOR in the skin samples obtained from patients
suffering from pruritic psoriasis (Tominaga et al., 2007).
Animal experiments showed that the density of free nerve
endings in the epidermis was higher in KOR knockout mice
compared with the wild phenotype. In addition, scratching
behaviour in KOR-deficient mice with dry skin dermatitis
was reduced compared to wild-type animals (Bigliardi and
Bigliardi-Qi, 2014). Of note, it has been shown that not only
centrally acting but also peripherally restricted KOR agonists,
such as ICI 204 448, inhibited chloroquine-induced pruritus
in mice (Inan and Cowan, 2004). These observations fully
justify further development of novel KOR ligands as novel
antipruritic agents.
SA, the active component of S. divinorum, has recently
been demonstrated to exhibit significant analgesic effects
(Fichna et al., 2012). It has also been shown to reduce the
number of itch responses in mice; however, the effect of SA
was weaker than other KOR agonists, such as TRK820, which
is probably due to the rapid degradation of SA in vivo (Wang
et al., 2005). Moreover, the potential of SA to become a drug
used in the clinical treatment of disorders dominated by pain
and itch is strongly hampered by its adverse effects, as it
rapidly crosses the blood–brain barrier and causes short-lived
hallucinations. Therefore attempts to develop new analogues
with similar activity have been undertaken. The fact that SA
analogues can be synthesized in the simple two-step reaction
from SA, which is readily available from accessible plant
material, may provide a significant advantage over currently
available semi-synthetic opioids, such as TRK820.
Here we found that PR-38, a novel SA analogue and a
mixed KOR/MOR ligand, attenuated pruritus after peripheral
administration, and this effect was blocked by the selective
MOR antagonist β-FNA. Moreover, this study provides evi-
dence for good bioavailability of PR-38, as we showed that
Figure 6
Antiscratch activity of PR-37 (A) and PR-38 (B) after oral administra-
tion (10 mg·kg−1) in mice. Data represent mean ± SEM of n = 6–8
mice for each experimental group. *P < 0.05, as compared with the
control group.
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this analogue maintains its antiscratch activity after oral
administration. This is in line with our recent report, where
we demonstrated that PR-38 is present in plasma at the
detectable level after oral administration (Salaga et al.,
2014b). Furthermore, the same study showed that PR-38 did
not produce any CNS-related side effects, which is an unques-
tionable advantage over ‘classical’ opioids (Salaga et al.,
2014b). Given both, a potent antipruritic effect and good
bioavailability, as well as the lack of CNS-related side effects,
PR-38 may become a scaffold for the design of novel com-
pounds that could be used as supplemental agents to treat
pruritus, also in patients receiving spinal opioid analgesics.
Figure 7
Effect of PR-37 on the CNS. (A) Effect of PR-37 (10 mg·kg−1, i.p.) on horizontal locomotor activity. (B) Effect of PR-37 (10 mg·kg−1, i.p.) on vertical
locomotor activity. (C) Effect of PR-37 (10 mg·kg−1, i.p) on time spent in the opened and closed areas of elevated o-maze. (D–I) Catwalk automated
gait analysis in mice after PR-38 administration (10 mg·kg−1, i.p.) Depicted are mean ratios ± SEM (8–10 mice per experimental group) of pawprint
intensity (D), print width (E), print area (F), max area (G), swing (H) and swing speed (I), separately, for front and hind paws. **P < 0.01, ***P <
0.001, as compared with the control group.
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In our study we also showed that another SA analogue,
PR-37, inhibited compound 48/80-induced pruritus in a dose-
dependent manner. In the case of PR-37, this effect was
blocked by the KOR antagonist norBNI. Of note, in vitro PR-37
also binds at DOR, but with low affinity (Ki = 4320 ± 680 nM).
However, the antiscratch activity of PR-37 was not blocked by
the DOR antagonist, which indicates that the interaction
between PR-37 and DOR is negligible for its antiscratch effect
(Polepally et al., 2013).
One of the main overall goals in our studies is to find a
novel SA analogue lacking the CNS-related side effects,
typical of the parent compound. It is widely known that SA
has a strong, short-acting psychoactive effect and its actions
in humans range from impaired motor activity, visual
effects, memory impairment and unresponsiveness to feel-
ings of anxiety/fear, distance from usual daily reality and
paranoia (Ranganathan et al., 2012; MacLean et al., 2013).
To determine the potential side effects of PR-37, we used the
same set of behavioural experiments and dosage as previ-
ously described for PR-38 (Salaga et al., 2014b). We observed
that the majority of parameters did not change after admin-
istration of PR-37, namely, the results obtained in the
O-maze test suggest no anxiogenic and/or anxiolytic activ-
ity and no effects on spontaneous locomotor activity were
found. However, we observed some significant disturbances
in several gait parameters suggesting that PR-37 affects neu-
romotor functions of the CNS. These data show that PR-37
and PR-38 differ in their ability to affect CNS-related func-
tions, in favour of the latter. A comparison of the structures
of both SA analogues is thus recommended, as it may lead
to the identification of certain moieties, which are respon-
sible for either induction of psychopharmacological
effects or determination of their ability to penetrate the
blood–brain barrier. Higher efficiency of PR-37 than PR-38
in crossing the blood–brain barrier could also explain,
at least partly, its longer and more potent antiscratch effect
in vivo.
The majority of recent studies focus on MOR and KOR
as targets for both pruritogenic and antipruritic compounds.
While it is generally accepted that stimulation of KOR
attenuates pruritus, it is still not clear whether pharmaco-
logical stimulation or blockade of MOR may have beneficial
effects (Bigliardi and Bigliardi-Qi, 2014). Moreover, centrally
administered MOR agonists were found to induce different
scratching responses. For example, a synthetic MOR agonist,
DAMGO, which is known for its higher efficacy at MOR
than morphine, induced a more intense pruritus than mor-
phine (Ko, 2014). Interestingly, it has been demonstrated
that MOP1D, an isoform of MOR, is responsible for
morphine-induced pruritus and that morphine-induced itch
is separable from morphine-induced analgesia in mice (Liu
et al., 2011).
As indicated by the in vitro and in vivo studies, PR-38 is a
mixed MOR/KOR agonist with about fivefold lower efficacy at
MOR. However, its antiscratch activity in vivo was blocked by
the MOR, but not the KOR, antagonist. Previously, we have
shown that the potent antinociceptive effect of PR-38 in
mouse models of visceral pain were also mediated by MOR
(Salaga et al., 2014b). Taking into account the data showing
the involvement of central MORs in the induction of pruri-
tus, we suggest that PR-38 does not activate the sites in the
CNS due to a very weak penetration through the blood–brain
barrier. However, this only partly explains the antipruritic
activity of PR-38, in particular, when our observations also
rule out the direct involvement of KOR. We hypothesize that
there is a possible cross-talk between MOR and KOR in this
process. If MOR-KOR heterodimers are formed, a signalling
cascade causing an antipruritic effect may be evoked exclu-
sively by activation of MOR, and in that way, the KOR
antagonist will not block it. A more in-depth mechanistic
study is needed to address this issue.
On the other hand, it may be hypothesized that PR-38
acts in vivo as a weak partial agonist or partial antagonist of
MOR. It may be expected that such low-efficacy MOR ligands
would antagonize scratching in contrast to high-efficacy
MOR ligands, which would induce it. Indeed, it has been
shown that a synthetic mixed KOR-agonist/MOR-partial
antagonist butorphanol is highly effective in the treatment of
intractable pruritus (Dawn and Yosipovitch, 2006; Lim et al.,
2008). Moreover, some authors postulate that the itch sensa-
tion in the periphery and CNS is the result of an imbalance
between MOR and KOR activities (Bigliardi and Bigliardi-Qi,
2014). Of interest, nalfurafine (TRK820), a mixed KOR
agonist/MOR- and DOR-partial agonist, was effective against
pruritus in animal studies (Togashi et al., 2002; Umeuchi
et al., 2003; Wang et al., 2005; Inan et al., 2009). Clinical trials
with nalfurafine are particularly encouraging, as they showed
its effectiveness against haemodialysis-associated pruritus,
both after intravenous and oral administration (Wikstrom
et al., 2005; Kumagai et al., 2010; Inui, 2012; Phan et al.,
2012; Benecke et al., 2013).
In conclusion, modification of the chemical structure of
SA produced analogues displaying antiscratch activity but
with a different pharmacological profile. One of these deriva-
tives, PR-38, elicited a significant antiscratch effect in vivo,
which was mediated by MOR, and retained its biological
activity after oral administration. It seems likely that PR-38
will be further developed due to its significant effects on the
pruritus combined with good bioavailability and the lack of
psychotropic side effects. PR-38 may also be used as a scaffold
for the further development of novel SA-derived agonists,
partial agonists, and KOR/MOR dual agonists that do not
cross the blood–brain barrier. On the other hand, based on
the structure of PR-37, it may be seen what types of chemical
modifications are needed to eliminate the potential CNS-
related side effects of SA. These data may be used in the future
for the design of novel SA derivatives with more desirable
therapeutic profiles.
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Figure S1 Confirmatory experiment demonstrating the
selectivity of β-FNA and norBNI (administered 2 h prior to
the respective agonist) at MOR and KOR receptors respec-
tively. (A) Morphine-induced locomotor hyperactivity is
blocked by pretreatment with β-FNA (1 mg·kg−1 s.c.) but not
norBNI (10 mg·kg−1, s.c.). (B) The effect of SA on total spon-
taneous locomotor activity is blocked by norBNI (10 mg·kg−1,
s.c.) but not β-FNA (1 mg·kg−1, s.c.). *P < 0.05, as compared
with the control group. #P < 0.05, as compared with mor-
phine or SA.
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